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Evidence of rickettsiae in Danish patients
tested for Lyme neuroborreliosis: a
retrospective study of archival samples
Lukas Frans Ocias1,2* , Ram Benny Dessau2, Anne-Mette Lebech3, Charlotte Sværke Jørgensen4,
Randi Føns Petersen4 and Karen Angeliki Krogfelt1
Abstract
Background: With a prevalence of 4.7–13% in Danish Ixodes ricinus ticks, Rickettsia helvetica is one of the most
frequently detected tick-borne organisms in Denmark. Most reports of human exposure have described
asymptomatic seroconversion or a mild, self-limiting flu-like illness but it has also been implicated as a cause of
subacute lymphocytic meningitis. Because Borrelia burgdorferi sensu lato (Bbsl) and R. helvetica are both found in the
same tick species, potential co-transmission is a possibility. We examined 1) the seroprevalence of anti-rickettsia
antibodies in patients investigated for Lyme neuroborreliosis (LNB), and 2) the cerebrospinal fluid (CSF) and sera of
same patients for the presence of Rickettsia DNA.
Methods: Ninety-nine sera and 87 CSF samples from patients with intrathecal synthesis of anti-Borrelia antibodies
and 101 sera and 103 CSF samples from patients with no detectable intrathecal synthesis were retrospectively
examined for this study. Sera were analyzed for antibodies against spotted fever group (SFG) rickettsiae and both
the CSF and sera were tested for Rickettsia DNA using a genus-specific real-time PCR.
Results: Of the patients tested for LNB, 32% (64/200) had IgG antibodies against SFG rickettsiae. Among patients
with confirmed intrathecal synthesis of Borrelia-specific antibodies, 38% (38/99) exhibited IgG antibodies. None of
these values were statistically significant when compared with sera from healthy blood donors (p = 0.7 and 0.19).
Rickettsia DNA was found in the CSF of 4% (8/190) of patients.
Conclusion: No statistically significant difference was found in the seroprevalence of anti-rickettsia antibodies in
patients tested for LNB and healthy blood donors, indicative of a low rate of exposure in this group of patients.
Eight patients showed evidence of Rickettsia DNA in the CSF, five of whom had LNB. However, cycle threshold (Ct)
values were high, indicating low concentrations of DNA, and no apparent alteration in the clinical manifestations of
LNB were noted in the medical records of these patients.
Keywords: Rickettsioses, Tick-borne infections, Tick-borne pathogens, Co-infection, Lyme neuroborreliosis, Neuroinfection
Background
With an annual incidence of over 3/100,000, Lyme neu-
roborreliosis (LNB) is the commonest bacterial neuroin-
fection in Denmark [1]. It is caused by spirochetes in the
Borrelia burgdorferi sensu lato (Bbsl) complex, transmit-
ted to humans by the tick vector Ixodes ricinus, also
known as the castor bean tick. Apart from Bbsl, several
other potentially pathogenic organisms have been identi-
fied in Danish I. ricinus ticks, including Anaplasma pha-
gocytophilum, Babesia spp., tick borne encephalitis virus
(TBEV), Rickettsia helvetica and most recently, Rickettsia
monacensis [2–6].
The Rickettsia genus consists of small, aerobic, obli-
gately intracellular Gram-negative organisms and can be
divided into two serotypically distinct groups: the spot-
ted fever group (SFG) and the typhus group (TG). Mem-
bers of the SFG rickettsiae can be found across the globe
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and are known for causing infections of varying patho-
genicity, ranging from the mild African tick-bite fever
(Rickettsia africae), endemic in sub-Saharan Africa and
the West Indies, to the more severe and potentially fatal
Rocky Mountain spotted fever (Rickettsia rickettsii) in
the Americas. Of the two Rickettsia spp. existing endemic-
ally in Denmark, R. helvetica is the most prevalent and is
also one of the most frequently encountered tick-borne
organisms in the country [3–5]. Most patients exposed to
this organism display subclinical infection or a mild,
self-limiting febrile illness with headache and myalgia,
only rarely accompanied by the often characteristic eschar
or rash seen in other forms of SFG rickettsioses [7–10].
However, it has also been implicated as a cause of sub-
acute lymphocytic meningitis [11, 12].
Because R. helvetica is transmitted by the same tick
vector as the Bbsl complex, co-transmission of both
agents is a possibility and has been shown to occur in
humans [13–15]. Recently, a Dutch study examining the
presence of rickettsiae in the cerebrospinal fluid (CSF) of
208 patients suspected of LNB, detected R. helvetica and
R. monacensis DNA in four and one of the patients, re-
spectively [14]. Apart from R. helvetica, meningitis has
also been associated with several other species of SFG
rickettsia including R. rickettsii, Rickettsia conorii, Rickett-
sia japonica and Rickettsia felis, reflecting the neuroinva-
sive potential in at least some of the species [16–20].
As Rickettsia spp. are intrinsically resistant to penicillin,
the treatment of choice for Lyme borreliosis, the clinical
significance and incidence of co-transmission needs to be
further examined in a Danish population. The aim of this
study was threefold; 1) to investigate the seroprevalence of
antibodies against SFG rickettsia in patients investigated
for LNB 2) to examine the presence of Rickettsia DNA in
the CSF and sera of same patients, and 3) to examine the
clinical significance of such a finding.
Methods
Study cohort
The study cohort consisted of archival samples of paired
sera and CSF from patients tested for LNB using the
intrathecal anti-Borrelia (IgM/IgG) antibody index (AI)
test. One-hundred and four paired samples were selected
from AI positive patients, indicating certain prior expos-
ure to I. ricinus ticks, and 110 paired samples were se-
lected from AI negative patients. As some of the archival
samples only had small remaining volumes, insufficient
for further testing, some of them had to be discarded. A
total of 99 sera and 87 CSF samples from AI positive pa-
tients, and 101 sera and 103 CSF samples from AI nega-
tive patients, remained for inclusion in this study after
duplicates and samples containing insufficient volumes
had been removed (Fig. 1).
All samples were collected in the months of June to
November during the years 2011–2015 and have been
stored at the State Serum Institute (SSI) at − 20 °C. The
serological analysis for LNB was during these years
mostly centralized at SSI and the samples thus represent
patients from across the whole country.
Intrathecal anti-Borrelia antibody index test
The intrathecal anti-Borrelia antibody index test had been
performed using an in-house capture enzyme-linked im-
munosorbent assay (ELISA) that uses native purified fla-
gellum from B. afzelii (strain DK1) as antigen [21]. The AI
had been calculated using the formula: (ODcsf/ODseru-
m)*(ODcsf − ODserum), with ODcsf and ODserum repre-
senting the optical density in CSF and sera, respectively.
An AI ≥0.3 is regarded as positive.
Rickettsia serology
The sera were examined for antibodies against SFG rick-
ettsiae using a commercially available indirect immuno-
fluorescense assay (IFA) (IF0100G, Rickettsia IFA IgG;
Focus Diagnostics, Inc., Cypress, CA, USA). Inactivated
R. rickettsii (RR) was used as antigen to detect SFG rick-
ettsiae. The samples were screened at dilutions of 1:64
(IgM) and 1:128 (IgG) and were titrated to end-point
fluorescence in two-fold dilutions. A titer of 1:64 or
above was considered positive for IgM. The cut-off for
IgG had previously, for diagnostic purposes, been raised
Fig. 1 Study flow-chart. CSF; cerebrospinal fluid; PCR; polymerase
chain reaction; IFA; indirect immunofluorescense assay. * = Six of the
AI negative sera samples contained insufficient volume for PCR
analysis and were therefore not analyzed using this method
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to 1:512, following testing of healthy Danish blood do-
nors, to achieve a specificity of 95% and reduce
cross-reactivity with other bacteria [22]. However, as this
elevated cut-off likely results in a loss of sensitivity, a
lower cut-off of 1:128 was used in this study. One hun-
dred and eleven serum samples from healthy Danish
blood donors served as controls for IgG and 60 blood
donor samples served as controls for IgM. These donor
samples provided an estimate of the background sero-
prevalence of anti-rickettsia antibodies in the Danish
general population.
Rickettsia PCR
All of the CSF samples and all, but six, of the sera were ex-
amined using real-time PCR for the presence of Rickettsia
DNA. All samples were centrifuged for 10 min at 15,000 g,
after which part of the supernatant was discarded leaving a
volume of 200 μl along with the pellet. Extraction of DNA
was achieved using the Qiagen QIAamp DNA Mini Kit
(Qiagen Danmark, Copenhagen, Denmark), and DNA was
eluted into a final volume of 75 μl. All extractions were
performed in a hooded bench with laminar air flow and
caution was exercised to prevent contamination. A
genus-specific real-time PCR with a reported sensitivity of
one copy of Rickettsia DNA per reaction, was used to amp-
lify a 74 bp fragment of the R. rickettsii citrate synthase
(CS) gene (gltA) using the primers CS-F and CS-R and the
probe CS-P [23]. This assay has previously been used to
detect Rickettsia spp., including R. helvetica, in Danish I.
ricinus ticks and previous quality assurance programs with
the Australian Rickettsial Reference Laboratory have
shown perfect matches with no false positive results [5].
Furthermore, the primers used are highly specific and have
been validated with no detectable cross-reactivity on med-
ically important bacteria as well as other members of the
order Rickettsiales including A. phagocytophilum and Bar-
tonella spp. [23]. One-hundred and three CSF samples
from patients examined for other neuroinfections than
LNB, primarily encephalitis/meningitis caused by the her-
pes simplex virus (HSV) or varicella zoster virus (VZV),
served as negative controls (Table 1). DNA from Rickettsia
australis (strain JC) in three 10-fold dilutions served as
positive controls.
Statistical analysis
Statistical significance was calculated with Fisher’s exact test
(two-tailed) and the two-sample Wilcoxon rank sum test
using the statistical software R Studio (v1.0.153) [24]. A
p-value ≤0.05 was considered to be statistically significant.
Results
Serology
Antibody titers for the AI positive patients, AI negative
patients and healthy blood donors are presented in Table 2.
When using a cut-off of 1:128 (one titer above the one
suggested by the manufacturer), 64 of the 200 patients
(32%) tested for LNB had detectable IgG antibodies and
four (2%) had detectable IgM antibodies against SFG rick-
ettsiae. The IgG seroprevalence was 38% (38/99), 26% (26/
101) and 30% (33/111) in the AI positive patients, the AI
negative patients and the healthy blood donors, respect-
ively. The seroprevalence was not significantly elevated in
the AI positive and AI negative patients compared with
healthy blood donors (p = 0.19 and 0.54). However, a
two-sample Wilcoxon rank sum test revealed a
non-significant tendency to higher titers in the AI positive
group (p = 0.08).
When using the routine, diagnostic cut-off of 1:512 [22],
12 patients in the AI positive group and five of the healthy
blood donors exhibited anti-rickettsia antibodies. This dif-
ference was, however, also non-significant (p = 0.07).
PCR
At the genus-level, Rickettsia DNA was identified in eight
of 190 (4%) archival CSF samples, with cycle threshold
(Ct) values ranging between 39 and 44. Compared with
the 103 negative controls, this is a non-significant differ-
ence (p = 0.054). However, five of these patients were AI
Table 1 Sample characteristics of negative control group (n =
103) consisting of CSF, with and without pleocytosis, from
patients examined for other neuroinfections than LNB
Control samples (n = 103)
Median age (IQR, range): 51 (33–63, 0–92)
CSF pleocytosis:
≤ 5 × 106/L, n: 82
> 5 × 106/L, n (median, IQR, range): 21 (14, 9–65, 6–4248)
CSF protein:
≤ 0.50 g/L, n: 64
> 0.50 g/L, n (median, IQR, range): 39 (0.69, 0.56–0.99, 0.51–2.30)
IQR interquartile range, CSF cerebrospinal fluid
Table 2 Antibody titers against SFG rickettsiae in the AI positive
group (a), the AI negative group (b), and the healthy blood
donors (c)
Antibody index positive (n = 99)
a. 1:64 1:128 1:256 1:512 1:1024 1:2048 1:4096
RR IgM 1 0 0 1 0 0 0
RR IgG – 12 14 7 5 0 0
b. Antibody index negative (n = 101)
RR IgM 0 2 0 0 0 0 0
RR IgG – 9 13 1 1 2 0
c. Blood donors (n = 111/60)
RR IgM 1 0 0 1 0 0 0
RR IgG – 18 10 4 1 0 0
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positive, reflecting a significantly increased probability of
detecting Rickettsia DNA in this subgroup compared with
the controls (p = 0.02). Sequencing was attempted but
failed on all eight samples. None of these patients dis-
played anti-Rickettsia antibodies in the corresponding
sera. No CSF in the negative control group, regardless of
biochemical findings, showed evidence of Rickettsia DNA
and no Rickettsia DNA could be detected in the sera. All
internal negative controls remained negative and all posi-
tive controls displayed positive reactions.
Cases
Hospital medical records were reviewed for the eight pa-
tients in whom Rickettsia DNA was detected in the CSF.
The clinical data are summarized in Table 3. Five of the pa-
tients had CSF pleocytosis with mononuclear predominance
and typical clinical signs indicative of LNB including periph-
eral facial palsy and radiculitis, sometimes accompanied by
fever or signs of meningismus like photophobia or nuchal ri-
gidity. All five of these patients were treated with intraven-
ous ceftriaxone. Out-patient follow-up 1 month after
discharge was performed in three of the patients revealing
complete recovery in two of the patients (Case 1 and 2) and
slight persisting headache and fatigue in the third (Case 5).
One patient had a PCR-verified enteroviral meningitis
with fever, headache and neck pain accompanied by
an unspecified rash but had recovered completely and
was free of symptoms at hospital discharge. Two pa-
tients (Case 6 and 7) had no CSF pleocytosis and pre-
sented with neurological symptoms.
One of the patients (Case 5) had, in the months prior
to hospital admission, experienced a tick bite in Sweden.
No other patients had any mention of international
travel, leading up to the hospital admission. As R. helve-
tica is also the most common tick-borne rickettsia found
in Sweden, all patients had thus most likely been in-
fected with this species or possibly, R. monacensis [25].
Discussion
We found no significant difference in the seropreva-
lence of antibodies against SFG rickettsiae between pa-
tients investigated for LNB and healthy blood donors
and no Rickettsia DNA in the tested sera, indicating
low rates of exposure to SFG rickettsiae in Danish pa-
tients with Lyme borreliosis. Eight patients showed evi-
dence of Rickettsia DNA in the CSF, five of whom were
Borrelia AI positive, reflecting a significantly increased
probability of detecting Rickettsia DNA in the AI posi-
tive subgroup compared with patients tested for other
neuroinfections than LNB (p = 0.02). Despite this, the
AI positive patients presented with typical clinical signs
of LNB with no apparent alteration in the clinical mani-
festations of this infection.
Serology
The high seroprevalence of IgG antibodies against SFG
rickettsiae among healthy blood donors is indicative of
considerable non-specific background reactivity, revealed
by the lowering of our titer cut-off for this study. Never-
theless, the absence of a significant difference in the
seroprevalence of antibodies between healthy blood do-
nors and patients examined for LNB, regardless of titer
cut-off and Borrelia AI, is indicative of low rates of ex-
posure in this group of patients.
Important caveats to be emphasized are that the pre-
cise time elapsed from being bitten to being tested is not
known and that the precise kinetics of the human anti-
body response to R. helvetica and R. monacensis have
not been studied, factors that could potentially impact
the current results. However, considering that adult Da-
nish patients with LNB are often diagnosed late in the
course of their disease with a median delay of 20 days
from the start of neurological symptoms until first hos-
pital contact, one can assume that enough time had
passed to allow seroconversion in most of the AI posi-
tive patients exposed to SFG rickettsiae [26].
Lastly, R. rickettsii, and not R. helvetica, was used as
IFA antigen in the current study. Rickettsia conorii is
often used as antigen to screen for SFG rickettsiae and
cross-reactivity between this species and R. helvetica has
previously been demonstrated [7, 14]. As R. rickettsii is
phylogenetically closely related to R. conorii and due to
the generally considerable homology between SFG rick-
ettsiae resulting in high levels of serological intra-group
cross-reactivity, we expect R. helvetica to be detectable
using this current assay, as has been suggested by a pre-
vious study [27]. This has been corroborated by prelim-
inary tests on Norwegian sera from patients seropositive
for R. helvetica, indicating that these antibodies are de-
tectable using R. rickettsii as antigen and the current
cut-offs (unpublished data).
PCR
Whether the detected Rickettsia DNA represents true
neuroinfection or not can be discussed. All internal
negative controls remained negative, making contamin-
ation less likely. Furthermore, Rickettsia DNA was not
detected in the negative control group, consisting of pa-
tients tested for other neuroinfections than LNB and
representing a range of varying biochemical values, re-
ducing the chances of it being an artifact. Sequencing
was attempted but failed on all eight samples, most
likely due to the small amounts of bacterial DNA in the
samples, as reflected in the high Ct values. However, the
general lack of discerning clinical features in these cases
and the apparent lack of pleocytosis and clinical signs of
infection in two of the subjects necessitates cautious in-
terpretation of these PCR findings. It is important to
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note that none of the patients received treatment with
doxycycline (Table 3). Despite Rickettsia spp. being in-
herently resistant to beta-lactam antibiotics [28] and
these patients thus never receiving any effective treatment
against their putative Rickettsia infection, all patients with
spinal fluid pleocytosis and available follow-up data recov-
ered from the acute phase of their infections, with two of
them experiencing a full recovery 1 month post treatment.
One of the previously described cases of putative R. helve-
tica neuroinfection had concomitant PCR-verified herpes
simplex meningitis and it is, likewise, unknown what role
R. helvetica played in this infection and how the patient
would have fared had he not received treatment with
doxycycline [12]. Furthermore, it is important to
emphasize that detection of bacterial DNA is not equiva-
lent to detecting the organism itself, and the present study
does not establish any causal relationship between these
findings and the clinical features of the patients.
Interestingly, none of the patients exhibiting DNA in
their CSF had detectable antibodies against SFG rickett-
siae. Possible explanations could be that the patients
were tested prior to the development of anti-rickettsia
antibodies, a lack of sensitivity in the IFA assay or sam-
ple contamination with rickettsial DNA. It is possible
that the lack of antibodies facilitated the detection of
Rickettsia DNA by allowing the bacteria to survive and
spread, as suggested by a recent study [29].
Strengths and limitations
The study is limited by its retrospective nature and its
use of frozen archival specimens of variable volume,
ill-suited for culture and lacking convalescent samples
for serology. However, the use of archival material also
allowed the inclusion of a greater number of patients
with a confirmed anti-Borrelia AI, ascertaining prior tick
exposure, than would have been possible in a reasonable
time frame following a prospective study design. It is im-
portant to remember that all samples had initially been
sent to a serological laboratory and have thus, not been
handled in a clean working environment appropriate for
PCR analysis, why potential sample contamination can-
not be ruled out. This also applies to the negative CSF
controls, many of which had previously been tested for
HSV/VZV using an intrathecal antibody index test.
However, contamination seems unlikely as we have
never amplified or cultured rickettsiae in our serological
laboratory and have only used commercial IFA kits with
preformed slides, on which the antigen is already fixed,
for serological analysis.
The effect of prolonged storage in − 20 °C freezers and
multiple cycles of thawing-freezing on the quality and yield
of potential bacterial DNA can also be discussed. The
former was not considered a major problem as R. helvetica
has previously been detected in CSF (using both culture
and PCR) after having been stored for over a year in a
− 20 °C freezers [11]. Regarding the latter, prior studies
on Treponema pallidum have shown only negligible ef-
fects of multiple freezing-thawing cycles on the quality
and yield of spirochetal DNA in CSF, and this is likely
the case for other forms of bacterial DNA as well [30].
Conclusion
Despite them being one of the commonest tick-borne or-
ganisms in Denmark, antibody reactivity against Rickettsia
spp. was not significantly increased in patients investigated
for LNB as compared with healthy blood donors. The
same was true when looking at the subgroup of patients
with a positive anti-Borrelia AI test, confirming a prior
tick bite. These findings indicate low levels of SFG rickett-
siae co-transmission in this group of patients.
Furthermore, eight patients displayed small amounts
of Rickettsia DNA in the CSF. However, the lack of CSF
pleocytosis in two of the patients, the complete or
near-complete clinical recovery in most of the patients,
despite being withheld doxycycline, and a general lack of
clear, discerning clinical features in all of the patients,
necessitates cautious interpretation of these results.
Should this CSF data indicate true rickettsial infection,
such occurrences appear to be rare and of uncertain sig-
nificance to the patient.
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